

Development of small molecule targeting FoxM1 for the treatment of colorectal cancer

Korea Research Institute of Chemical Technology(KRICT)



ONCOLOGY	Lead
Product Type	Small molecule
Indication	Solid cancers including colorectal, lung and breast cancers
Target	FoxM1 (Forkhead box M1)
MoA(Mechanism of Action)	Inhibition of FoxM1
Competitiveness	<ul style="list-style-type: none"> Several small molecules are currently undergoing biological testing. Among them, FDI-6, developed at University of Cambridge, is recognized as the most active compound.
Development Stage	Lead
Route of Administration	P.O.